Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/673
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | MOLENBERGHS, Geert | - |
dc.contributor.author | BURZYKOWSKI, Tomasz | - |
dc.contributor.author | ALONSO ABAD, Ariel | - |
dc.contributor.author | BUYSE, Marc | - |
dc.date.accessioned | 2005-03-18T14:52:10Z | - |
dc.date.available | 2005-03-18T14:52:10Z | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | Statistical Methods in Medical Research, 13(3). p. 177-206 | - |
dc.identifier.issn | 0962-2802 | - |
dc.identifier.uri | http://hdl.handle.net/1942/673 | - |
dc.description.abstract | The last couple of decades have seen a large amount of activity in the area of surrogate marker and surrogate endpoint validation, both from a clinical and a statistical perspective. Prentice1 made a pivotal contribution in the context of a single trial. Subsequently, the framework he proposed has been discussed, criticized, and extended. An important class of extensions considers several rather than a single trial. Recently, a lot of work has been done in this so-called hierarchical or meta-analytic framework. In this paper, we review both the single trial and the hierarchical framework. A number of applications, scattered throughout the literature, are brought together. We outline the statistical issues involved in trying to validate surrogate endpoints. Clearly statistical evidence should only be seen as a component in a decision making process that also involves a number of clinical and biological considerations. | - |
dc.description.sponsorship | We gratefully acknowledge support from Belgian IUAP=PAI network ‘Statistical Techniques and Modeling for Complex Substantive Questions with Complex Data’. | - |
dc.format.extent | 595236 bytes | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | en | - |
dc.publisher | ARNOLD | - |
dc.rights | (C) Arnold 2004 | - |
dc.subject | Surrogate Markers | - |
dc.subject | Clinical trials | - |
dc.title | A perspective on surrogate endpoints in controlled clinical trials | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 206 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 177 | - |
dc.identifier.volume | 13 | - |
local.bibliographicCitation.jcat | A1 | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
local.class | dsPublValOverrule/author_version_not_expected | - |
dc.identifier.doi | 10.1191/0962280204sm362ra | - |
dc.identifier.isi | 000221873600001 | - |
item.fullcitation | MOLENBERGHS, Geert; BURZYKOWSKI, Tomasz; ALONSO ABAD, Ariel & BUYSE, Marc (2004) A perspective on surrogate endpoints in controlled clinical trials. In: Statistical Methods in Medical Research, 13(3). p. 177-206. | - |
item.validation | ecoom 2005 | - |
item.fulltext | With Fulltext | - |
item.accessRights | Open Access | - |
item.contributor | MOLENBERGHS, Geert | - |
item.contributor | BURZYKOWSKI, Tomasz | - |
item.contributor | ALONSO ABAD, Ariel | - |
item.contributor | BUYSE, Marc | - |
crisitem.journal.issn | 0962-2802 | - |
crisitem.journal.eissn | 1477-0334 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
burt13.pdf | Published version | 581.29 kB | Adobe PDF | View/Open |
SCOPUSTM
Citations
47
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
42
checked on May 16, 2024
Page view(s)
110
checked on Sep 7, 2022
Download(s)
280
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.